Ozmosi | Bencycloquidium Drug Profile

Product Description

Bencycloquidium bromide nasal spray is effective and safe for persistent allergic rhinitis (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32623510/)

Mechanisms of Action: M1 Antagonist, M3 Antagonist Binder

Novel Mechanism: Yes

Modality: Unknown

Route of Administration: Nasal, Inhalant

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Yingu Pharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Rhinitis, Allergic

Phase 1: Chronic Obstructive Pulmonary Disease

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
ChiCTR2500107341	ChiCTR2500107341	N/A	/Completed	Sneezing	2024-02-27
ChiCTR1900020497	ChiCTR1900020497	N/A	Recruiting	Chronic Obstructive Pulmonary Disease	2019-04-03
ChiCTR2000030924	ChiCTR2000030924	N/A	Completed	Rhinitis, Allergic	2013-01-15
CTR20211344	CTR20211344	N/A	Active, not recruiting	Sneezing	None	2025-04-29	Patient Enrollment\|Trial Status
CTR20212431	CTR20212431	P1	Completed	Chronic Obstructive Pulmonary Disease	2022-06-22	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT05038202	YG-BLT-PMS001	P4	Active, not recruiting	Rhinitis, Allergic	2024-04-30	2024-03-05	Primary Endpoints

Recent News Events

Date	Type	Title
07/01/2023	PubMed	[A multi-center observation of the therapeutic efficacy of Bencycloquidium bromide in the treatment of seasonal allergic rhinitis with predominant symptoms of rhinorrhea].
02/01/2021	PubMed	Safety, Tolerability and Pharmacokinetics of Bencycloquidium Bromide, a Novel Inhaled Anticholinergic Bronchodilator, in Healthy Subjects: Results from Phase I Studies.
11/01/2020	PubMed	Bencycloquidium bromide nasal spray is effective and safe for persistent allergic rhinitis: a phase III, multicenter, randomized, double-blinded, placebo-controlled clinical trial.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Bencycloquidium

Alternative Names: bencycloquidium Clinical Status: Inactive Latest Update: 2024-03-04 Latest Update Note: Clinical Trial Update